RxDoctor Payments Data

Patricia Durham

Family · Lubbock, TXNPI 1780649632

Payments from drug & device makers

$1,050in general payments, 2019–2025

Across 17 payments — averaging $61.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$187
  • Amgen$123
  • Novo Nordisk$123
  • AbbVie$122
  • Enterra Medical, Inc.$101
  • AstraZeneca$97
  • plus $297 from 7 others

What the payments were for

  • Food & beverage$1,050100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,050 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$199,730
Medicare patients
382
Services billed
2,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$19,752
NuedextaDextromethorphan Hbr/Quinidine21$15,229
GemtesaVibegron49$12,077
XareltoRivaroxaban28$11,092
TrulicityDulaglutide18$9,660
JardianceEmpagliflozin27$8,244
BrilintaTicagrelor27$5,905
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$4,920
Acetaminophen-CodeineAcetaminophen With Codeine65$3,877
Levothyroxine Sodium256$3,517
Celecoxib79$3,447
Icosapent Ethyl24$3,377
LantusInsulin Glargine,hum.Rec.Anlog15$2,783
Buspirone Hcl153$2,670
Atorvastatin Calcium193$2,378

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$19,75245 claims
Avanir Pharmaceuticals, Inc.Nuedexta$88$15,22921 claims
Johnson & JohnsonXarelto$21$11,09228 claims
AstraZenecaBrilinta$97$5,90527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 15,456 family providers in Texas.

Other family in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →